Sequencing Therapies and Using the Most Effective Options First

Panelists discuss how sequencing strategies influence long-term disease control and patient survival in EGFR-positive non–small cell lung cancer (NSCLC). They explore the advantages of initiating treatment with the most efficacious agents upfront, weighing this against the potential loss of future options. The conversation examines resistance evolution, patient-specific factors, and clinical evidence supporting early use of potent targeted combinations. Ultimately, the panel underscores the trend toward frontloading the most effective treatments to achieve deeper, longer-lasting responses.